Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis
- 15 October 2008
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 178 (8), 814-821
- https://doi.org/10.1164/rccm.200802-327oc
Abstract
The prevalence in cystic fibrosis (CF) of respiratory cultures with methicillin-resistant Staphylococcus aureus (MRSA) has dramatically increased over the last 10 years, but the effect of MRSA on FEV(1) decline in CF is unknown. To determine the association between MRSA respiratory infection and FEV(1) decline in children and adults with CF. This was a 10-year cohort study using the Cystic Fibrosis Foundation patient registry from 1996-2005. We studied individuals who developed new MRSA respiratory tract infection. Repeated-measures regression was used to assess the association between MRSA and FEV(1) decline, adjusted for confounders, in individuals aged 8-21 years and adults (aged 22-45 yr). Two different statistical models were used to assess robustness of results. The study cohort included 17,357 patients with an average follow-up of 5.3 years. During the study period, 1,732 individuals developed new persistent MRSA infection (> or =3 MRSA cultures; average, 6.8 positive cultures) and were subsequently followed for an average of 3.5 years. Even after adjustment for confounders, rate of FEV(1) decline in individuals aged 8-21 years with persistent MRSA was more rapid in both statistical models. Their average FEV(1) decline of 2.06% predicted/year was 43% more rapid than the 1.44% predicted/year in those without MRSA (difference, -0.62% predicted/yr; 95% confidence interval, -0.70 to -0.54; P < 0.001). Effect of MRSA on FEV(1) decline in adults was not clinically significant. Persistent infection with MRSA in individuals with CF between the ages of 8 and 21 years is associated with a more rapid rate of decline in lung function.Keywords
This publication has 22 references indexed in Scilit:
- Risk of Infection and Death due to Methicillin‐ResistantStaphylococcus aureusin Long‐Term CarriersClinical Infectious Diseases, 2008
- Emergence of an Epidemic Clone of Community-Associated Methicillin-Resistant Panton-Valentine Leucocidin-Negative Staphylococcus aureus in Cystic Fibrosis Patient PopulationsJournal of Clinical Microbiology, 2007
- Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung functionPediatric Pulmonology, 2007
- Compliance of Clinical Microbiology Laboratories in the United States with Current Recommendations for Processing Respiratory Tract Specimens from Patients with Cystic FibrosisJournal of Clinical Microbiology, 2006
- Immune evasion by staphylococciNature Reviews Microbiology, 2005
- Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infectionJournal of Hospital Infection, 2004
- Comparison of Mortality Associated with Methicillin‐Resistant and Methicillin‐SusceptibleStaphylococcus aureusBacteremia: A Meta‐analysisClinical Infectious Diseases, 2003
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisNew England Journal of Medicine, 1995
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993